DataMEDS AI Stock Skyrockets 500% Following Helomics AI Acquisition

Key Facts

1DataMEDS AI (MEDS) shares rallied 5x on Wednesday following the completion of its acquisition of Helomics AI cancer diagnostics laboratory.

In a move reflecting the growing trend of integrating AI technologies into the healthcare sector, DataMEDS AI shares experienced an extraordinary rally. According to reports, the company's stock surged 500% on Wednesday following the completion of its acquisition of Helomics AI, a laboratory specializing in cancer diagnostic research. This massive rally was driven by investor optimism regarding the company's strategic shift toward AI-powered precision oncology.

This significant price movement reflects a sharp reaction to transformative deals within the biotech sector, where the stock breaking above key moving averages contributed to the upward momentum. Per market data, the stock's trading was characterized by high volatility coinciding with the closing of the deal, which positions the company at the forefront of the advanced cancer research market.

Looking at price levels, MEDS stock closed at $1.62 on September 15, 2026, with a wide intraday range between a low of $0.865 and a high of $3.85. Traders are currently monitoring the sustainability of these price levels following this major jump, given the absence of immediate upcoming economic catalysts specifically targeting the healthcare sector in the calendar.